TY - JOUR
T1 - Genetic predisposition in sarcomas
T2 - clinical implications and management
AU - Connolly, Elizabeth A.
AU - Boye, Kjetil
AU - Bonvalot, Sylvie
AU - Kratz, Christian P.
AU - Leithner, Andreas
AU - Malkin, David
AU - Messiou, Christina
AU - Miah, Aisha B.
AU - Pantziarka, Pan
AU - Timmermann, Beate
AU - van der Graaf, Winette T.A.
AU - Thomas, David M.
AU - Stacchiotti, Silvia
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/5
Y1 - 2025/5
N2 - Recent studies indicate up to 20% of sarcomas may be associated with predisposition genes, and this number will probably increase as genetic testing becomes more available. Evidence on the management of patients with sarcoma and genetic predisposition remains, however, scarce. This review compiles available research on genetic predisposition syndromes associated with sarcoma and sarcoma treatment within such syndromes, addressing key gaps in knowledge. We explore the current evidence on how genetic predisposition may influence treatment decisions and clinical management, focusing on surgery, radiotherapy, systemic treatment, and surveillance. Evidence-based recommendations are currently not available for most syndromes, and we have therefore included pragmatic advice for clinicians. Unanswered questions and unmet needs are also identified, underscoring the importance of multidisciplinary input from specialists such as geneticists, radiologists, surgeons and oncologists. The review stresses the need for future research to improve clinical outcomes for patients with sarcoma and genetic predisposition. Funding: No funding has been provided for this work.
AB - Recent studies indicate up to 20% of sarcomas may be associated with predisposition genes, and this number will probably increase as genetic testing becomes more available. Evidence on the management of patients with sarcoma and genetic predisposition remains, however, scarce. This review compiles available research on genetic predisposition syndromes associated with sarcoma and sarcoma treatment within such syndromes, addressing key gaps in knowledge. We explore the current evidence on how genetic predisposition may influence treatment decisions and clinical management, focusing on surgery, radiotherapy, systemic treatment, and surveillance. Evidence-based recommendations are currently not available for most syndromes, and we have therefore included pragmatic advice for clinicians. Unanswered questions and unmet needs are also identified, underscoring the importance of multidisciplinary input from specialists such as geneticists, radiologists, surgeons and oncologists. The review stresses the need for future research to improve clinical outcomes for patients with sarcoma and genetic predisposition. Funding: No funding has been provided for this work.
UR - http://www.scopus.com/inward/record.url?scp=105002493567&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2025.103203
DO - 10.1016/j.eclinm.2025.103203
M3 - Review article
AN - SCOPUS:105002493567
SN - 2589-5370
VL - 83
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 103203
ER -